1.98
Aptevo Therapeutics Inc stock is traded at $1.98, with a volume of 122.62K.
It is down -4.35% in the last 24 hours and down -36.74% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$2.07
Open:
$2.03
24h Volume:
122.62K
Relative Volume:
0.06
Market Cap:
$6.51M
Revenue:
$12.99M
Net Income/Loss:
$-23.72M
P/E Ratio:
-0.0204
EPS:
-97.2514
Net Cash Flow:
$-23.28M
1W Performance:
-1.00%
1M Performance:
-36.74%
6M Performance:
-97.15%
1Y Performance:
-99.30%
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
APVO
Aptevo Therapeutics Inc
|
1.98 | 6.81M | 12.99M | -23.72M | -23.28M | -97.25 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Published on: 2025-08-21 02:09:31 - classian.co.kr
What’s the RSI of Aptevo Therapeutics Inc. stockTrade Performance Summary & High Return Stock Watch Alerts - mustnews.co.kr
APVO stock plunges to 52-week low at $3.62 amid steep annual decline - MSN
Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - MarketScreener
Aptevo highlights prostate cancer bispecific antibody candidate By Investing.com - Investing.com Nigeria
Aptevo's New Prostate Cancer Drug Shows Promise with Targeted Immune Response Technology - Stock Titan
Aptevo Therapeutics APVO Q2 2025 Earnings Preview Downside Risk Over Lack of Revenue Growth - AInvest
Aptevo Therapeutics Reports Q2 2025 Financials and Business Update, Raises $15.9M, and Advances Mipletamig and APVO455 Candidates - AInvest
Aptevo Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aptevo Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update | APVO Stock News - GuruFocus
Aptevo Therapeutics Inc. SEC 10-Q Report - TradingView
Aptevo Therapeutics reports Q2 EPS ($8.40) vs. ($1,236.96) last year - TipRanks
Aptevo Reports 85% Remission in Q2 - The Motley Fool
Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - ACCESS Newswire
Aptevo Reports Breakthrough: 85% Remission in AML Trial, Launches New Solid Tumor Program - Stock Titan
Evaluating Aptevo Therapeutics Inc. with trendline analysisReal Time Trade Execution Alert Plan - Newser
Is Aptevo Therapeutics Inc. likely to announce a buybackBest ROI Stocks This Month - sisain.net
Why Aptevo Therapeutics Inc. stock attracts strong analyst attentionWeekly Chart Watchlist with Trade Guidance - Newser
Historical volatility pattern of Aptevo Therapeutics Inc. visualizedRisk-Managed Swing Setup and Signal Analysis - Newser
Using data models to predict Aptevo Therapeutics Inc. stock movementSafe Entry Screening with Data Backed Analysis - Newser
Aptevo Therapeutics Inc expected to post a loss of $83.20 a shareEarnings Preview - TradingView
Aptevo Therapeutics and 60 Degrees Pharmaceuticals to be Featured on Bloomberg TV's RedChip Small Stocks, Big Money Show - AInvest
Aptevo Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Daily Corinthian
Aptevo Therapeutics (APVO) Expected to Announce Quarterly Earnings on Thursday - Defense World
Multi factor analysis applied to Aptevo Therapeutics Inc.Real Chart Based Opportunity Identification - Newser
How volatile is Aptevo Therapeutics Inc. stock compared to the marketDiscover top stock picks for aggressive growth - Jammu Links News
What institutional investors are buying Aptevo Therapeutics Inc. stockMaximize portfolio value with timely trades - Jammu Links News
Is Aptevo Therapeutics Inc. a good long term investmentMaximize portfolio growth with expert advice - Jammu Links News
How does Aptevo Therapeutics Inc. generate profit in a changing economyDiscover undervalued stocks ready to soar - Jammu Links News
How does Aptevo Therapeutics Inc. compare to its industry peersDiscover high-impact stocks for your portfolio - Jammu Links News
Is it the right time to buy Aptevo Therapeutics Inc. stockHigh-octane financial growth - Jammu Links News
How strong is Aptevo Therapeutics Inc. company’s balance sheetBuild a portfolio for long-term financial success - Jammu Links News
Why is Aptevo Therapeutics Inc. stock attracting strong analyst attentionCapitalize on emerging growth stocks - Jammu Links News
Does Aptevo Therapeutics Inc. stock perform well during market downturnsTremendous wealth creation - Jammu Links News
When is Aptevo Therapeutics Inc. stock expected to show significant growthInvest smarter with actionable market insights - Jammu Links News
What drives Aptevo Therapeutics Inc. stock priceUnlock daily market insights for better trades - Jammu Links News
What are the latest earnings results for Aptevo Therapeutics Inc.Build a portfolio for long-term financial success - Jammu Links News
Should I hold or sell Aptevo Therapeutics Inc. stock in 2025Unlock your trading potential today - Jammu Links News
What are Aptevo Therapeutics Inc. company’s key revenue driversBuild wealth faster with consistent growth stocks - Jammu Links News
What are the technical indicators suggesting about Aptevo Therapeutics Inc.Wealth Building Trend Scanner For Smart Trading - Jammu Links News
Aptevo Therapeutics Inc. Shows Support at Fibonacci LevelFree Elite Traders Group - beatles.ru
What is Aptevo Therapeutics Inc. company’s growth strategyInvest smarter with advanced market data - Jammu Links News
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):